Lutetium-177 radioligand therapy
Cancer-seeking molecules carrying the radioactive metal lutetium-177, which delivers short-range radiation to tumours it binds; approved for neuroendocrine tumours and prostate cancer.
Overview
Lutetium-177 emits beta particles with a range of a few millimetres and gamma rays that allow imaging, making it the workhorse isotope of radioligand therapy. Lutathera (Lu-177 dotatate, approved 2018) targets somatostatin receptors on neuroendocrine tumours, and Pluvicto (Lu-177 PSMA-617, approved 2022) targets PSMA on prostate cancer; both improved outcomes in randomised trials. Supply of no-carrier-added lutetium, dosimetry and combinations with earlier lines of therapy are the current frontiers.
How it works
A peptide or small molecule with high affinity for a tumour receptor is chelated to Lu-177 and infused; bound molecules irradiate the cell and its neighbours over the isotope's 6.6-day half-life.
- Randomised survival benefit in two diseases
- Companion PET imaging selects patients
- Tolerable toxicity profile
- Isotope supply and logistics
- Marrow and kidney dose limits
- Resistance and heterogeneous uptake
Latest papers
topQuery for this technology: (TITLE:"Lutetium-177 radioligand therapy" OR ABSTRACT:"Lutetium-177 radioligand therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lutetium-177 radioligand therapy, not a curated reading list.
Similar pages
not linked directly; found by shared links- CompanyPOINT Biopharma
Shares Somatostatin receptor 2, PSMA, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonKen Herrmann
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA, Neuroendocrine tumours.
- PairingBeta radioligand → alpha radioligand
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Lutetium-177 vipivotide tetraxetan, PSMA.
- PersonLouise Emmett
Shares Lutetium-177 vipivotide tetraxetan, PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Lutetium-177 vipivotide tetraxetan, PSMA.
- PersonJonathan R. Strosberg
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonShahneen Sandhu
Shares Lutetium-177 vipivotide tetraxetan, PSMA, Radioligand therapy (beta emitters), Prostate cancer.